Radiopharm Theranostics Limited (RADX) Analyst Estimates & Price Targets

Radiopharm Theranostics Limited (RADX) — Price $1.67 HealthcareBiotechnology — NASDAQ

Latest reported results:

Wall Street analyst estimates for Radiopharm Theranostics Limited (RADX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.

Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging medical conditions.

Analyst Consensus

Strong Buy0
Buy1
Hold0
Sell0
Strong Sell0
Total analysts1
Avg rating (1-5)1.00

Valuation Ratios

Price / Book2.21
EV / EBITDA-1.01
Dividend Yield0.00%

Income Statement (10y)

Year20222023202420252026
Revenue$8831$292359$299228$3.6M$2.7M
Cost of Revenue000$3.6M$4.8M
Gross Profit$8831$292359$299228$39276-$2.1M
Research & Development$4.1M$13.8M$17.6M$27.5M0
Selling, General & Admin$10.8M$13.0M$15.2M$16.5M$15.9M
Operating Expenses$19.9M$34.8M$36.9M$38.2M$64.7M
Operating Income-$19.9M-$34.5M-$36.6M-$38.2M-$66.8M
EBITDA-$18.0M-$31.2M-$44.1M-$38.2M-$66.8M
Interest Expense$9.3M$86091$642888$65300$109939
Pre-tax Income-$30.3M-$34.6M-$47.9M-$38.2M-$55.7M
Income Tax$44397$38005$96364$103292-$53249
Net Income-$30.3M-$34.6M-$47.9M-$38.3M-$53.9M
EPS$-29.76$-33.00$-36.00$-5.28$-4.56
EPS (Diluted)$-29.76$-33.00$-36.00$-5.28$-4.56
Shares Outstanding (Diluted)$1.0M$1.0M$1.3M$6.9M$11.8M

Price

Price$1.67
Market Cap$2M
ExchangeNASDAQ
CountryAU

Related companies: ADXN · BCLI · CDIO · CYCN · IBO · KTTA · MTNB

Explore sector: Healthcare · Biotechnology

More sections of RADX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks